IMMUVANCE
Registro de marca extinto (Madri)
Marca Nominativa depositada no INPI em
26/06/2020 por CytoDyn Inc.,
processo nº 501548940, nas classes 05, 42, 44.
O processo não está mais ativo — o nome pode estar livre para novo pedido.
| Número do processo | 501548940 |
|---|
| Situação | Registro de marca extinto (Madri) |
|---|
| Apresentação | Nominativa |
|---|
| Natureza | Madri
Produto/Serviço |
|---|
| Data do depósito | 26/06/2020 |
|---|
| Data da concessão | 05/10/2021 |
|---|
| Vigência até | 09/06/2022 |
|---|
| Titular | CytoDyn Inc. |
|---|
| CNPJ/CPF do titular | — |
|---|
| UF · País | — · US |
|---|
Classes e especificação
Therapeutic preparations, namely, antibodies for use in targeting the C-C chemokine receptor type 5 [CCR5] cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19.;
Scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.;
Providing medical information, via a website; providing information in the field of using antibodies for medical treatment, for use in targeting the CCR5 cell receptor, via a website; providing health and medical information, via a website, namely, providing information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting.;